Blardi P, Messa G, Puccetti L, La Placa G, Ghezzi A
Istituto di Clinica Medica Generale e Terapia Medica, Università, Siena.
Recenti Prog Med. 1995 Jul-Aug;86(7-8):282-9.
We evaluated the mesoglycan effects on the coagulative-fibrinolytic system in 10 patients with euglobulin lysis time (ELT) over 180 minutes. A mathematical model was used to analyze such phenomena. 100 mg of mesoglycan was administered to 10 patients for 14 days. The following parameters were evaluated: tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), euglobulin lysis time (ELT), plasminogen, alpha 2 antiplasmin, prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), and fibrinogen. Those parameters were evaluated on the first and on the last day of the mesoglycan treatment at the following times: 0 (basal), 2, 4, 6, 8, 10 and 12 hours. Our results suggest that the mesoglycan is able to reduce a profibrinolytic activity without any influence on the coagulative-fibrinolytic system, at the baseline conditions and after chronic administration. The pharmacodynamic study and the statistical analysis using our mathematic model resulted to be statistically significant.
我们评估了硫酸软骨素对10例优球蛋白溶解时间（ELT）超过180分钟患者凝血-纤溶系统的影响。使用数学模型分析此类现象。给10例患者服用100mg硫酸软骨素，持续14天。评估以下参数：组织纤溶酶原激活物（t-PA）、纤溶酶原激活物抑制剂（PAI-1）、优球蛋白溶解时间（ELT）、纤溶酶原、α2抗纤溶酶、凝血酶原时间（PT）、活化部分凝血活酶时间（aPTT）、凝血酶凝结时间（TCT）和纤维蛋白原。在硫酸软骨素治疗的第一天和最后一天的以下时间点评估这些参数：0（基础值）、2、4、6、8、10和12小时。我们的结果表明，在基线条件和长期给药后，硫酸软骨素能够降低纤溶活性，而对凝血-纤溶系统无任何影响。使用我们的数学模型进行的药效学研究和统计分析具有统计学意义。
